The Indian pharmaceuticals market’s growth this May has been the lowest in two years, impacted by a drop in sales of fixed dose combination drugs, fresh price cuts and a lower-than-expected uptake, according to pharmaceutical market research company AIOCD PharmaTrack.
For May, the pharmaceuticals market grew by 7.7% compared to 11.6% during the same month last year, reaching sales of Rs 99,476 crore over a 12-month period based on Moving Annual Total (MAT), according to an agency release. The country’s FDC market dropped 14.6% and is now valued at Rs 196 crore and anti-infectives, derma and respiratory were the worst-hit segments, it added. Fixed dose combination (FDC) drugs are products that have a combination of two or more therapeutic ingredients in a single dose. Indian drug makers were more affected by the drop in volumes in FDCs than multinational drug makers in the country, according to PharmaTrack.